<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608816</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #040910-HAAF in T1DM, Q4</org_study_id>
    <secondary_id>Ro1 DK06903-03</secondary_id>
    <nct_id>NCT00608816</nct_id>
  </id_info>
  <brief_title>Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q4</brief_title>
  <official_title>Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epinephrine is one of the important hormones in the defense of hypoglycemia. We will test the&#xD;
      hypothesis that antecedent hypoglycemia will blunt the metabolic, neuroendocrine and&#xD;
      cardiovascular effects of subsequent epinephrine infusion in Type 1 DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When a person had previously experienced bouts of low blood sugar, or hypoglycemia, his or&#xD;
      her counterregulatory responses to hypoglycemia would be weakened. This is especially true&#xD;
      and important for a person with Type 1 diabetes, because it will cause him or her to be&#xD;
      vulnerable to another bout of hypoglycemia, and cause hypoglycemia unawareness, which can&#xD;
      lead to serious or even life-threatening consequences. Epinephrine is one of the important&#xD;
      hormones in the defense of hypoglycemia. We will test the hypothesis that antecedent&#xD;
      hypoglycemia will blunt the metabolic, neuroendocrine and cardiovascular effects of&#xD;
      subsequent epinephrine infusion in Type 1 DM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catecholamine levels</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic euglycemic glucose clamp study on day 1 Hyperinsulinemic euglycemic clamp study on day 2 with epinephrine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic hypoglycemic glucose clamp x 2 on day 1 Hyperinsulinemic euglycemic clamp with epinephrine infusion on Day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinephrine</intervention_name>
    <description>Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinephrine</intervention_name>
    <description>Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  28 (14 males, 14 females) conventionally treated Type 1 diabetic patients with HA1C &gt;&#xD;
             8.5%&#xD;
&#xD;
          -  28 (14 males, 14 females) intensively treated Type 1 diabetic patients with HA1C &lt; 7%&#xD;
&#xD;
          -  28 (14 males, 14 females) non-diabetic controls&#xD;
&#xD;
          -  Age 18-45 yr.&#xD;
&#xD;
          -  Had diabetes for 2-15 years if diabetic subject&#xD;
&#xD;
          -  No clinical evidence of diabetic tissue complications, no cardiovascular disease&#xD;
&#xD;
          -  Body mass index 21-27kg · m-2&#xD;
&#xD;
          -  Normal bedside autonomic function&#xD;
&#xD;
          -  Normal results of routine blood test to screen for hepatic, renal, and hematological&#xD;
             abnormalities&#xD;
&#xD;
          -  Female volunteers of childbearing potential: negative HCG pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of poor health: any current or prior disease condition that alters&#xD;
             carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease&#xD;
&#xD;
          -  Hemoglobin of less than 12 g/dl&#xD;
&#xD;
          -  Abnormal results following screening tests&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Subjects unable to give voluntary informed consent&#xD;
&#xD;
          -  Subjects with a recent medical illness&#xD;
&#xD;
          -  Subjects with known liver or kidney disease&#xD;
&#xD;
          -  Subjects taking steroids&#xD;
&#xD;
          -  Subjects taking beta blockers&#xD;
&#xD;
          -  Subjects on anticoagulant drugs, anemic, or with known bleeding diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N. Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Steve Davis</investigator_full_name>
    <investigator_title>Chairman of Medicine, University of Maryland, Baltimore</investigator_title>
  </responsible_party>
  <keyword>epinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

